No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RNA Avidity Biosciences
- 22.730
- -0.310-1.35%
Close Apr 19 16:00 ET
- 23.340
- +0.610+2.68%
Post 19:45 ET
1.81BMarket Cap-7810P/E (TTM)
23.590High22.240Low1.01MVolume22.890Open23.040Pre Close23.02MTurnover1.53%Turnover RatioLossP/E (Static)79.84MShares27.66052wk High3.62P/B1.49BFloat Cap4.82552wk Low--Dividend TTM65.76MShs Float37.460Historical High--Div YieldTTM5.86%Amplitude4.825Historical Low22.821Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
FYBR, BCRX and SABR Are Among After Hour Movers
Express News | Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing
Arthur A Levin, Director, on April 03, 2024, sold 20,000 shares in Avidity Biosciences (RNA) for $542,214. Following the Form 4 filing with the SEC, Levin has control over a total of 268,702 shares of
Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
Avidity Biosciences(RNA.US) Director Sells US$542.21K in Common Stock
$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 20,000 shares of Common Stock on Apr 3, 2024 at an average price of $27.1107 for a total value of $542.21K.Source: Announcement What is state
Comments
Update
$Avidity Biosciences(RNA.US$ Avidity Biosciences Reports Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations Of PMO In Muscle Following A Single Dose In Healthy Volunteers From Phase 1/2 EXPLORE44 Trial For Duchenne Muscular Dystrophy
Benzinga· 4 mins ago
Benzinga· 4 mins ago
The Federal Reserve's commentary and forthcoming inflation report holds potential for significant market impact. Positive future prospects for Boeing are boosting its shares, while an escalated collaboration between Avidity Biosciences and Bristol-Myers Squibb garners positive sentiment and lifts Avidity's stocks.
1
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg